Biotech Pivot, Nasdaq Compliance March 23, 2026 Conduit Pharmaceuticals’ ambitious shift from real estate to biotech is facing headwinds, with a low market cap and Nasdaq listing concerns prompting a reverse stock split. Conduit Pharmaceuticals Faces Critical Juncture After Pivot to Biotech The transformation from a special purpose acquisition company (SPAC) focused on real estate … Read more
Inovio Pharmaceuticals Investors Face Deadline in Securities Class Action Investors who purchased Inovio Pharmaceuticals, Inc. (NASDAQ: INO) securities between October 10, 2023, and December 26, 2025, may be eligible to participate in a securities class action lawsuit. A lead plaintiff deadline of April 7, 2026, has been set for those wishing to take a leading … Read more
Iran Conflict: A Looming Shadow Over Pharmaceutical Supply Chains The recent escalation of conflict in the Middle East hasn’t yet caused widespread disruption to global pharmaceutical supplies, but experts warn that the potential for significant impact is growing. While current production in the immediate conflict zone represents a minor fraction of global output – just … Read more
CNBC Cures: A Turning Tide for Rare Disease Awareness and Innovation The launch of CNBC Cures, spearheaded by Becky Quick and her sister, marks a significant shift in how rare diseases are discussed and addressed. What began as a personal mission – driven by Quick’s own family’s experience with a rare disease diagnosis – has … Read more
India’s Ozempic Revolution: Will Cheaper Weight Loss Drugs Reach US Shores? The global weight-loss landscape is on the cusp of a dramatic shift. This weekend marks a pivotal moment as Indian pharmaceutical companies gain the green light to manufacture and sell generic versions of Ozempic and Wegovy, the blockbuster drugs transforming diabetes and obesity treatment. … Read more
Lilly’s Retatrutide: A New Era in Diabetes and Weight Management? Eli Lilly’s investigational drug, retatrutide, is generating significant buzz after demonstrating impressive results in a late-stage trial for Type 2 diabetes. The findings, released today, suggest a potential breakthrough in managing both blood sugar and weight – a historically challenging combination for individuals with the … Read more
Novo Nordisk CEO Calls for Radical Shift in Australia’s Approach to Chronic Disease Australia faces a “health challenge of the century” – chronic disease, with obesity as a key driver. That’s the message delivered by Novo Nordisk CEO Mike Doustdar at the National Press Club in Canberra on March 16, 2026. But his address wasn’t … Read more
From Plastic Waste to Parkinson’s Treatment: A Revolution in Sustainable Pharma? A groundbreaking study published in Nature Sustainability details a remarkable feat of bioengineering: transforming discarded plastic into levodopa (L-DOPA), a crucial medication for managing Parkinson’s disease. Researchers have engineered Escherichia coli bacteria to “upcycle” poly(ethylene terephthalate) – commonly known as PET – into this … Read more
The “Fugitive” Scenario: Pharma Scandals in the Age of Scrutiny The 1993 thriller “The Fugitive” – a staple for many, including STATus Report host Alex Hogan – presents a chillingly plausible scenario: a pharmaceutical giant knowingly pushing a dangerous drug to market. The film’s plot, centered around falsified clinical trial data for the drug Provasic … Read more
Cancer Immunotherapy: A New Target Emerges as Cells ‘Barf’ Proteins Researchers have identified a surprising location for a key protein, Src, on the surface of cancer cells – a place it shouldn’t be. This discovery, reported in Science, could unlock new avenues for immunotherapy, particularly for solid tumors, which have historically been hard to treat … Read more